None listed
Conditions
Interventions
Intervention group: Intervention group: This study examines the bioequivalence of nicorandil tablets produced by a domestic company with a foreign brand sample. We have only one intervention group and
Sponsors
Modava Pharmaceutical Company
Eligibility
Sex/Gender
Male
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: The weight range of participating candidates should be between 60-100 kg All candidates must be non-smokers Candidates should be healthy in terms of physical examination, ECG and the following laboratory tests: Hemoglobin, Hematocrit, Red and White Blood Count, MCV (Mean Body Volume), MCH (Mean Body Hemoglobin), Routine Urinalysis, Total Cholesterol, Triglyceride, Total Proteins, albumin, uric acid, total bilirubin, alkaline phosphatase, gamma glutamyl transpeptidase (?-GT), aspartate aminotransferase (AST), alanine aminotransferase (ALT), urea, creatinine and fasting blood glucose Volunteers who have agreed to an informed consent form
Exclusion criteria
Exclusion criteria: History of allergic or adverse reaction to nicorandil or any similar product Volunteers with blood pressure less than 60/90 mm Hg or higher than 90/140 mm Hg. smokers People who have participated in other clinical studies or bioequivalence studies within 3 months before the first day of use Individuals who donated whole blood or blood components within 2 months within 2 weeks prior to the first dose of the study product(s)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma concentration of the drug. Timepoint: 13 sampling time till 8 h. Method of measurement: LCMSMS. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHamed Hamishehkar
Drug Applied Research Center, Tabriz University of Medical Sciences
Outcome results
None listed